Figures & data
Figure 1 Patient flow through the inclusion and exclusion criteria.
![Figure 1 Patient flow through the inclusion and exclusion criteria.](/cms/asset/bd757889-569a-4927-9361-27bef74f3a44/dcop_a_52557_f0001_b.jpg)
Table 1 Characteristics of arformoterol and nebulized SABA patients during initial hospitalization
Figure 2 Unadjusted all-cause 30-day readmission rates for arformoterol-treated and nebulized SABA-treated patients by APR-DRG severity.
Abbreviations: APR-DRG, 3M™ All Patient Refined™-Diagnosis Related Groups; neb-SABA, nebulized short-acting β2 agonist.
![Figure 2 Unadjusted all-cause 30-day readmission rates for arformoterol-treated and nebulized SABA-treated patients by APR-DRG severity.](/cms/asset/89c7219d-2d24-4624-b95d-38fd304f5c82/dcop_a_52557_f0002_c.jpg)
Table 2 Logistic regression model